A Delaware-based pharmaceutical company is reportedly close to finalizing a major acquisition that could be worth as much as $2 billion, according to a Financial Times report published Sunday.
Incyte Pharma is approaching a deal to acquire Star Therapeutics, a company that focuses on developing treatments for blood disorders, according to sources familiar with the negotiations cited by the Financial Times.
Under the proposed agreement, the biotechnology firm would provide $1.25 billion in immediate cash payments to Star’s venture capital investors, with an additional $750 million tied to achieving specific performance targets, the report indicated.
The news report could not be independently confirmed by Reuters at this time.
